Bavarian Nordic CEO says short-term focus is on growth of vaccine business
Last month, Bavarian Nordic had to shelve the development of a vaccine candidate against RSV virus. In the coming years, the company will cut back on R&D and acquisitions, says Paul Chaplin.
After last month’s RSV vaccine flop, Bavarian Nordic will in the short term focus on growing its travel vaccine business, while acquisitions and research and development (R&D) will be less important. This was announced by CEO Paul Chaplin at an investor meeting on Monday afternoon, according to Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Bavarian Nordic CEO says R&D efforts won't be discontinued
For subscribers
